Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
AssigneeArvinas Operations, Inc.
InventorsYimin Qian, Hanqing Dong, Jing Wang
Life of this patent
Estimating the term…
Loading patent…
AssigneeArvinas Operations, Inc.
InventorsYimin Qian, Hanqing Dong, Jing Wang
Estimating the term…
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
A compound that is:
A compound that is:
A compound that is:
A compound that is:
A method of treating breast cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is:
Dependencies are inferred from the claim text.